 The FDA has placed a clinical hold on Viking Therapeutics Incs NASDAQ: VKTX Phase 1b trial of VK0214 in patients with X-linked adrenoleukodystrophy X-ALD. The FDA has requested an additional preclinical study before continuing the Phase 1b study of VK0214 in X-ALD, not due to any findings from ongoing or previously completed studies. 